This is a preview of subscription content, log in via an institution to check access.
Reference
Socal MP, et al. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. Value in Health : 17 Feb 2020. Available from: URL: https://doi.org/10.1016/j.jval.2019.12.007
Rights and permissions
About this article
Cite this article
Uptake of biosimilar filgrastim: room for improvement, potential savings. PharmacoEcon Outcomes News 848, 33 (2020). https://doi.org/10.1007/s40274-020-6646-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6646-3